RESEARCH ARTICLE


Effect of Sodium Valproate on Weight, Body Mass Index, Uric Acid, Vitamin D3, Blood Insulin, and Serum Lipid Profile in Children



Mohammad Vafaee-Shahi1, Fahimeh Soheilipour2, Parisa Mohagheghi3, Aina Riahi4, *, Nafise-Sadat Borghei5, Atefeh Talebi6
1 Pediatric Growth and Development Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Rasool Akram Complex Hospital, Iran University of Medical Sciences, Tehran, Iran
3 Rasool Akram Complex Hospital, Iran University of Medical Sciences, Tehran, Iran
4 Minimally Invasive Surgery Research Center, Iran University of Medical Science, Tehran, Iran
5 Rasool Akram Complex Hospital, Iran University of Medical Sciences, Tehran, Iran
6 Colorectal Research Center, Iran University of Medical Science, Tehran, Iran


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 991
Abstract HTML Views: 467
PDF Downloads: 122
ePub Downloads: 79
Total Views/Downloads: 1659
Unique Statistics:

Full-Text HTML Views: 710
Abstract HTML Views: 169
PDF Downloads: 96
ePub Downloads: 58
Total Views/Downloads: 1033



Creative Commons License
© 2022 Vafaee-Shahi et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Minimally Invasive Surgery Research Center, Iran University of Medical Science, Tehran, Iran; Tel: +989121571355; Fax: 982166525328; E-mail: riahi.a@iums.ac.ir


Abstract

Introduction:

Due to the high prevalence of epilepsy and the use of sodium valproate as an antiepileptic drug by these patients, accurate recognition of its side effects and its effects on serum lipids profile, liver enzymes, uric acid level, and thyroid function tests, especially in cases that need long-term treatment seems essential. This study aimed to evaluate the effects of sodium valproate on weight, body mass index (BMI), vitamin D3, blood insulin, uric acid level, and serum lipids profile in children with newly diagnosed epilepsy.

Materials and Methods:

This prospective study was performed on 30 children between 3 and 8 years of age who suffered from newly diagnosed epilepsy and received sodium valproate as monotherapy. Data including demographic information (age, sex, height, weight, and waist and hip circumference of children), as well as clinical characteristics, such as liver enzymes (ALT, AST, ALK-P), serum lipids level (TG, TC, HDL-C, LDL-C), thyroid tests (TSH, T4), fasting blood sugar (FBS), uric acid level, 25 OH Vitamin D3 (Vit-D3), and blood insulin level of children before and six months after the consumption of sodium valproate, were examined.

Results:

The mean weight of children before and six months after the start of sodium valproate treatment was 18.54±2.99 and 21.13±3.93 (kg), respectively. This difference was statistically significant (P=0.005). Also, the mean weight Z-score of children before and after taking sodium valproate was -2.497 and -2.293, respectively, which was statistically significant too. In addition to weight gain, there was also a significant increase in the abdominal and hip circumference of children after taking valproate, whereas the increase in mean BMI before and after valproate administration was not statistically significant (P=0.114). However, mean weight gain, as well as the increase in the waist and hip circumference, had no relationship with gender (P> 0.05). Also, sodium valproate significantly increased the ALT level (P=0.046). Moreover, sodium valproate did not affect other liver function markers (AST), thyroid hormones (TSH, T4), fasting blood sugar (FBS), uric acid level, 25 OH Vit-D3, and the children's blood insulin levels (P> 0.05).

Conclusion:

According to the findings of this study, it can be concluded that sodium valproate is a good drug for children between 3 and 8 years of age, but it should be noted that taking this drug increases the chance of obesity in children. The main side effect of this drug is weight gain. Due to the significant increase in ALT enzyme, as observed in this study, it is recommended to check liver enzymes before, one, and six months after starting treatment as it can prevent the irreversible permanent side effects of this drug.

Keywords: Epilepsy, Antiepileptic drugs, Sodium valproate, Body mass index, Children, Uric acid, Obesity, Liver enzymes.